Stay updated on REGN728 Safety & Tolerability Clinical Trial
Sign up to get notified when there's something new on the REGN728 Safety & Tolerability Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FpElDgI7nuoZY_od8eyCPttOq4v4.uncropped.jpg&w=3840&q=75)
Latest updates to the REGN728 Safety & Tolerability Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoChange DetectedThe study has been updated to version v2.10.0, indicating a new release with potentially significant changes from the previous version v2.9.7.SummaryDifference0.7%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check24 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Revision: v2.9.0' has been updated to 'FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : Randomized Interventional Model : Single Group Assignment Masking : Double ( Participant Investigator ) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Cohort 1 Dose 1 versus placebo Biological : REGN728 2 Subcutaneous Cohorts (dose 1, 2) Experimental : Cohort 2 Dose 2 versus placebo Biological : REGN728 2 Subcutaneous Cohorts (dose 1, 2) Primary Outcome Measures Outcome Measure Measure Description Time Frame The primary endpoint in the study is the percentage of subjects with treatment emergent adverse events, reported from the administration of study drug on day 1 to the completion of the study on day 106. 106 days Revision: v2.9.1'. This change represents an update in the study details and primary outcome measures.SummaryDifference9%
Stay in the know with updates to REGN728 Safety & Tolerability Clinical Trial
Enter your email address, and we'll notify you when there's something new on the REGN728 Safety & Tolerability Clinical Trial page.